Scinai Immunotherapeutics Ltd. American Depositary Shares SCNI · Stock Open Scinai Immunotherapeutics Ltd. American Depositary Shares in new tab
Scinai Immunotherapeutics Ltd. American Depositary Shares Analysis (SCNI)
Is Scinai Immunotherapeutics Ltd. American Depositary Shares a good investment? Scinai Immunotherapeutics Ltd. American Depositary Shares (SCNI) is currently trading at 1.91 USD.
In terms of valuation, the stock trades at a P/E ratio of 0.05. This relatively low multiple may signal that Scinai Immunotherapeutics Ltd. American Depositary Shares is undervalued compared to historical market norms.
Earnings Schedule: Scinai Immunotherapeutics Ltd. American Depositary Shares is expected to release its next earnings report on Dec. 2, 2026.
Investor FAQ
Does Scinai Immunotherapeutics Ltd. American Depositary Shares pay a dividend?
No, it does not currently pay a dividend.
What asset class is Scinai Immunotherapeutics Ltd. American Depositary Shares?
Scinai Immunotherapeutics Ltd. American Depositary Shares is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Dec. 2, 2026. The company currently has a trailing EPS of 31.43.
Company Profile
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
| Split Date | Split Ratio to 1 |
|---|---|
| Nov. 25, 2022 | 1:10 |
| May 21, 2024 | 1:10 |
| Aug. 21, 2026 | 1:10 |
Community Discussion